Recently, the National Medical Products Administration (NMPA) released a significant document—the "2020 Annual Medical Device Registration Work Report". The report indicates that in 2020, the NMPA approved a total of 26 representative invention patents (applications) for innovative medical devices. Among these is the Hydrogen-Oxygen Nebulizer produced by Asclepius Meditec.
Hydrogen-Oxygen Nebulizer Wins Another Honor!
The "2020 Annual Medical Device Registration Work Report" is a significant annual report released by the National Medical Products Administration. It covers the registration and approval of medical devices in China over the past year, summarizing the latest major advancements in the innovation of medical devices in China.
National Medical Products Administration Official Website Screenshot
"2020 Annual Medical Device Registration Work Report" Query URL:
https://www.nmpa.gov.cn/yaowen/ypjgyw/20210205111730106.html?type=pc&m=
File Index Number: XZXK-2021-107
In this report, the section that has garnered significant attention from the medical industry and represents the direction of China's medical innovation is the "Registration and Approval of Innovative Medical Devices and Other Products". Each product listed represents a major innovative advancement in China's medical device sector.
The report states: "In 2020, the National Medical Products Administration approved a total of 26 innovative medical device products for market release. The core technologies of these innovative products all possess Chinese invention patent rights or have had their invention patent applications publicly disclosed by the Patent Administration Department under the State Council. The main working principles/mechanisms of action of the products are domestically pioneering and have significant clinical application value".
The hydrogen-oxygen nebulizer has been honored to be included in the list due to its achievements in clinical research on hydrogen-oxygen medicine.
The National Medical Products Administration introduces the hydrogen-oxygen nebulizer as follows:
Asclepius Meditec Hydrogen-Oxygen Nebulizer
The product consists of a main unit (including ultrasonic nebulization module, water electrolyser module, humidification filtration module, computer control module) and accessories (nasal mask). This product is used in medical institutions to assist in improving symptoms (including dyspnea, cough, and sputum production) in adult patients with acute exacerbation of chronic obstructive pulmonary disease requiring hospitalization.
National Medical Products Administration Official Website Screenshot
Asclepius Meditec Hydrogen-Oxygen Nebulizer
The Asclepius Meditec hydrogen-oxygen nebulizer utilizes a hydrogen-oxygen mixed gas to reduce malignant free radicals, and has mechanisms of action including anti-inflammatory, antioxidant, and anti-apoptotic effects. Because hydrogen possesses oxygen-carrying capacity, inhaling the hydrogen-oxygen mixed gas can improve oxygen utilization, reduce airway resistance, alleviate symptoms of dyspnea, and assist patients in combating diseases such as COPD.
For this reason, during the pandemic, the hydrogen-oxygen nebulizer was included three times in the national diagnosis and treatment protocols, used to address symptoms like dyspnea in over 3,000 patients fighting against COVID-19.
Screenshot of the Eighth Edition of COVID-19 Diagnosis and Treatment Protocol
As Asclepius Meditec vigorously promotes clinical trials, the therapeutic potential of hydrogen-oxygen medicine in chronic diseases such as diabetes, tumors, Alzheimer's disease, and hypertension is continuously being explored. As of now, Asclepius Meditec has been granted 239 patents. In collaboration with experts and professors from over 50 teaching hospitals across the country, nearly 100 foundational research projects have been completed, with 53 SCI papers published (covering respiratory diseases, neurological disorders, metabolic dysfunction, tumors, etc.). More hydrogen-oxygen medical research is being conducted on a large scale.
